The information contained in the Organizational Database (ODB) is provided for informational purposes only. There is no implied endorsement by NORD. NORD does not promote or endorse participation in any specific organization. The information is subject to change without notice. Every effort is made to ensure that the details for each entry are as current as possible.
LAM Treatment Alliance, Inc.
50 Church Street
Cambridge, MA 02138
The LAM Treatment Alliance is a voluntary, non-profit organization that is a leading force in advancing the treatment and cure for Lymphangioleiomyomatosis (LAM) through innovating, re-thinking, fostering, and aggressively funding high-impact initiatives and supporting patients in gaining access to multi-disciplinary clinical care and access to the knowledge in the research pipeline. LAM Treatment Alliance catalyzes high-performance partnerships between foundations, academic labs, government institutions and industry and works closely with new media technology, top labs, leading clinical centers and patient partners throughout the globe in order to accelerate the pace of discovery. LAM is a rare progressive multisystem disorder that predominantly affects women of childbearing age. It occurs in women who have tuberous sclerosis, and also in women who do not have a heritable genetic disorder. LAM is characterized by the spread and uncontrolled growth (proliferation) of specialized cells (smooth muscle cells) in certain organs of the body, especially the lungs. Common symptoms associated with LAM include coughing and/or difficulty breathing (dyspnea), especially following periods of exercise or exertion. Affected individuals may also experience complications including collapse of a lung or fluid accumulation around the lungs (pleural effusion). The disorder is progressive and, in some cases, may result in chronic respiratory failure.
The National Organization for Rare Disorders (NORD) web site, its databases, and the contents thereof are copyrighted by NORD. No part of the NORD web site, databases, or the contents may be copied in any way, including but not limited to the following: electronically downloading, storing in a retrieval system, or redistributing for any commercial purposes without the express written permission of NORD. Permission is hereby granted to print one hard copy of the information on an individual disease for your personal use, provided that such content is in no way modified, and that credit for the source (NORD) and NORD’s copyright notice are included on the printed copy. Any other electronic reproduction or other printed versions are strictly prohibited.
NORD's Rare Disease Information Database is copyrighted and may not be published without the written consent of NORD.